JP2021518374A5 - - Google Patents
Info
- Publication number
- JP2021518374A5 JP2021518374A5 JP2020550082A JP2020550082A JP2021518374A5 JP 2021518374 A5 JP2021518374 A5 JP 2021518374A5 JP 2020550082 A JP2020550082 A JP 2020550082A JP 2020550082 A JP2020550082 A JP 2020550082A JP 2021518374 A5 JP2021518374 A5 JP 2021518374A5
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- pharmaceutical composition
- composition according
- dapanstril
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862645999P | 2018-03-21 | 2018-03-21 | |
| US62/645,999 | 2018-03-21 | ||
| PCT/US2019/022770 WO2019182981A1 (en) | 2018-03-21 | 2019-03-18 | Methods for treating melanoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518374A JP2021518374A (ja) | 2021-08-02 |
| JP2021518374A5 true JP2021518374A5 (cg-RX-API-DMAC7.html) | 2022-03-15 |
| JP7229565B2 JP7229565B2 (ja) | 2023-02-28 |
Family
ID=67987925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550082A Active JP7229565B2 (ja) | 2018-03-21 | 2019-03-18 | メラノーマを治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11857529B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3768384B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7229565B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111867678B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3094307A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020009552A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019182981A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12121565B2 (en) * | 2019-09-13 | 2024-10-22 | Duke University | Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies |
| EP4045009A4 (en) * | 2019-10-14 | 2023-11-01 | Olatec Therapeutics LLC | METHOD FOR TREATING BREAST CANCER |
| EP4387729A4 (en) * | 2021-08-19 | 2025-07-09 | Olatec Therapeutics Inc | METHODS OF TREATMENT OF PARKINSON'S DISEASE |
| WO2026035767A1 (en) * | 2024-08-06 | 2026-02-12 | Olatec Therapeutics, Inc. | Methods for treating melanoma metastasis to liver and lungs |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013006708A (es) * | 2010-12-15 | 2013-09-13 | Olatec Ind Llc | Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor. |
| CA2875053C (en) * | 2012-06-05 | 2020-07-14 | Olatec Industries Llc | Pharmaceutical composition for treating inflammation and pain |
| JP6185575B2 (ja) * | 2012-06-05 | 2017-08-23 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 皮膚炎症性疾患の治療方法 |
| JP6929792B2 (ja) * | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| EP3288980B1 (en) * | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| EP3445761A1 (en) * | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| ES2970485T3 (es) * | 2017-01-06 | 2024-05-29 | Olatec Therapeutics Llc | Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares |
| EP3589370A4 (en) * | 2017-01-06 | 2020-11-18 | Olatec Therapeutics LLC | MULTIPLE SCLEROSIS TREATMENT METHOD |
| US20210254056A1 (en) | 2017-05-05 | 2021-08-19 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
| WO2019152627A1 (en) * | 2018-01-31 | 2019-08-08 | Olatec Therapeutics Llc | Method for preventing or treating alzheimer's disease |
-
2019
- 2019-03-18 JP JP2020550082A patent/JP7229565B2/ja active Active
- 2019-03-18 CN CN201980020523.3A patent/CN111867678B/zh active Active
- 2019-03-18 WO PCT/US2019/022770 patent/WO2019182981A1/en not_active Ceased
- 2019-03-18 CA CA3094307A patent/CA3094307A1/en active Pending
- 2019-03-18 EP EP19771591.5A patent/EP3768384B1/en active Active
- 2019-03-18 MX MX2020009552A patent/MX2020009552A/es unknown
-
2020
- 2020-09-15 US US17/021,733 patent/US11857529B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3788047T3 (fi) | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi | |
| MY201603A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| JP2017149726A5 (cg-RX-API-DMAC7.html) | ||
| IL292265B2 (en) | Methods for treating chronic lymphocytic leukemia using 2-(2,6-dioxopyridin-3-yl)-4-((2-fluoro-4((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3-dione) | |
| MX2023010064A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo. | |
| IL273188B2 (en) | Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor | |
| RU2018109902A (ru) | Виды комбинированной терапии для лечения рака | |
| WO2018005519A3 (en) | Cancer treatment combinations | |
| JP2021535175A5 (cg-RX-API-DMAC7.html) | ||
| CN115916778A (zh) | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 | |
| MY204915A (en) | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener | |
| MX2020007971A (es) | Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. | |
| EP4599894A3 (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| FI3661510T3 (fi) | Menetelmiä käyttäytymismuutosten hoitamiseksi | |
| CN111699174A (zh) | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| BR112021018169A2 (pt) | Composto para o controle de diabetes de felinos | |
| JP2023088996A5 (cg-RX-API-DMAC7.html) | ||
| AR115913A1 (es) | Formas de dosificación oral biodisponibles, uso, métodos | |
| JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| RU2008148597A (ru) | Фармацевтические комбинации | |
| JP2022512158A5 (cg-RX-API-DMAC7.html) | ||
| JP2020506169A5 (cg-RX-API-DMAC7.html) | ||
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| JP2006528190A5 (cg-RX-API-DMAC7.html) |